Telomerase activity and telomere lengths in various cell lines: Changes of telomerase activity can be another method for chemosensitivity evaluation

International Journal of Oncology

Volumn 13, Issue 3, 1998, Pages 489-495

  Park, Kyu Hyun ^a   Rha, Sun Young ^a,b   Kim, Chang Han ^c   Kim, Tae Soo ^a   Yoo, Nae Choon ^a,b   Kim, Joo Hang ^a,b   Roh, Jae Kyung ^a,b   Noh, Sung Hoon ^a   Min, Jin Sik ^a,b   Lee, Kyong Sik ^a   Kim, Byung Soo ^a,b   Chung, Hyun Cheol ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

Chemosensitivity; Telomerase; Telomere lengths

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; TELOMERASE;

ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; STOMACH CANCER; TELOMERE;

EID: 13144293036     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.3.489     Document Type: Article

References (32)

1. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
2. Harley CB and Kim NW: Telomerase and cancer. In: Important Advances in Oncology. De Vita VT, et al (eds.) Lippincott-Raven Publ., Philadelphia pp57-67, 1996.
3. Wynford-Thomas D: Proliferative lifespan checkpoints: cell-type specificity and influence on tumour biology. Eur J Cancer 33: 716-726, 1997.
4. Bryan TM, Englezou A, Dunham A and Reddel RR: Telomere length dynamics in telomerase-positive immortal human cell populations. Exp Cell Res 239: 370-378, 1998.
5. Wright WE, Shay JW and Piatyszek MA: Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 23: 3794-3795, 1995.
6. Bryan TM, Englezou A, Gupta J, Bacchetti S and Reddel RR: Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14: 4240-4248, 1995.
7. Rogalla P, Rohen C, Bonk U and Bullerdiek J: Telomeric repeat fragment lengths are not correlated to histological grading in 85 breast cancers. Cancer Lett 106: 155-161, 1996.
8. Bryan TM and Reddel RR: Telomere dynamics and telomerase activity in in vitro immortalized human cells. Eur J Cancer 33: 767-773, 1997.
9. Landberg G, Nielsen NH, Nilsson P, Emdin SO, Cajander J and Roos G: Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res 57: 549-554, 1997.
10. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S and Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56: 645-650, 1996.
11. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Amgen EST Program, Bass MB, Arruda L and Robinson MO: A mammalian telomerase-associated protein. Science 275: 973-977, 1997.
12. Breslow RA, Shay JW, Gazdar AF and Srivastava S: Telomerase and early detection of cancer: a National Cancer Institute Workshop. J Natl Cancer Inst 89: 618-623, 1997.
13. Ohyashiki K, Ohyashiki JH, Nishimaki J, Toyama K, Ebihara Y, Kato H, Wright WE and Shay JW: Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res 57: 2100-2103, 1997.
14. Holt SE, Wright WE and Shay JW: Multiple pathways for the regulation of telomerase activity. Eur J Cancer 33: 761-766, 1997.
15. Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, Kodama T, Piatyszek MA, Shay JW and Matsuura Y: Telomerase activity in gastric cancer. Cancer Res 55: 3258-3262, 1995.
16. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA and Shay JW: Telomerase activity in human breast tumors. J Natl Cancer Inst 88: 116-122, 1996.
17. Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K, Shay JW, Matsuura Y and Yokoyama T: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 57: 326-331, 1997.
18. Nakatani K, Yoshimi N, Mori H, Yoshimura S, Sakai H, Shinoda J and Sakai N: The significant role of telomerase activity in human brain tumors. Cancer 80: 471-476, 1997.
19. Tsao J, Zhao Y, Lukas J, Yang X, Shah A, Press M and Shibata D: Telomerase activity in normal and neoplastic breast. Clin Cancer Res 3: 627-631, 1997.
20. Norrback KF and Roos G: Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 33: 774-780, 1997.
21. Engelhardt M, Drullinsky P, Guillem J and Moore MAS: Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 3: 1931-1941, 1997.
22. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA and Sukumar S: Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 57: 2144-2147, 1997.
23. Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB, Wright WE and Shay JW: Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation inducing agents. Clin Cancer Res 2: 799-803, 1996.
24. Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, Izbicka E, Windle B and von Hoff DD: Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol 8: 1063-1074, 1997.
25. Kim NW: Clinical implications of telomerase in cancer. Eur J Cancer 33: 781-786, 1997.
26. Parkinson EK: Do telomerase antagonists represent a novel anticancer strategy? Br J Cancer 73: 1-4, 199.
27. Raymond E, Sun D, Chen SF, Windle B and von Hoff DD: Agents that target telomerase and telomeres. Pharm Biotechnol 7: 583-591, 1996.
28. Rha SY, Park KH, Kim TS, Kim JH, Roh JK, Min JS, Lee KS, Kim BS and Chung HC: Semi-quantitative comparison of terminal restriction fragment length and telomerase in breast cancer for biotherapy. J Korean Cancer Assoc 29: 231-241, 1998.
29. Park KH, Rha SY, Kim TS, Lee BC, Park SH, Chung HC, Lee WY, Kim JH, Roh JK, Lee KS, Min JS and Kim BS: Increment of telomerase activity with breast cancer progression. J Korean Cancer Assoc 29: 1032-1040, 1998.
30. Faraoni I, Turriziani M, Masci G, Vecchis LD, Shay JW, Bonmassar E and Graziani G: Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3: 579-585, 1997.
31. Melana SM, Holland JF and Pogo BGT: Inhibition of cell growth and telomerase activity of breast cancer cell in vitro by 3′-Azido-3′-deoxythymidine. Clin Cancer Res 4: 693-696, 1998.
32. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitcell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-947, 1987.